Shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $154.75, but opened at $150.55. Moderna shares last traded at $148.65, with a volume of 28,769 shares.
A number of analysts recently weighed in on the stock. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $135.00 to $180.00 in a report on Friday, January 21st. UBS Group began coverage on shares of Moderna in a research report on Friday, January 21st. They issued a “neutral” rating and a $221.00 target price for the company. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Moderna from $175.00 to $155.00 and set a “hold” rating for the company in a research report on Monday, March 7th. Barclays decreased their target price on shares of Moderna from $404.00 to $210.00 in a research report on Friday, February 25th. Finally, Morgan Stanley increased their target price on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $242.71.
The firm’s fifty day simple moving average is $158.07 and its 200 day simple moving average is $224.10. The company has a market capitalization of $61.20 billion, a price-to-earnings ratio of 5.30, a PEG ratio of 0.94 and a beta of 1.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.76 and a quick ratio of 1.60.
In related news, CEO Stephane Bancel sold 9,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 26th. The shares were sold at an average price of $158.00, for a total transaction of $1,422,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 24th. The shares were sold at an average price of $150.67, for a total transaction of $3,013,400.00. The disclosure for this sale can be found here. Insiders sold 206,054 shares of company stock valued at $33,851,454 over the last three months. 17.30% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Baillie Gifford & Co. raised its position in Moderna by 8.4% during the fourth quarter. Baillie Gifford & Co. now owns 45,772,079 shares of the company’s stock valued at $11,625,193,000 after acquiring an additional 3,554,725 shares in the last quarter. Norges Bank bought a new position in Moderna during the fourth quarter valued at approximately $773,229,000. Geode Capital Management LLC raised its position in Moderna by 71.6% during the third quarter. Geode Capital Management LLC now owns 5,759,961 shares of the company’s stock valued at $2,210,437,000 after acquiring an additional 2,404,103 shares in the last quarter. Bank of New York Mellon Corp raised its position in Moderna by 94.3% during the third quarter. Bank of New York Mellon Corp now owns 2,717,705 shares of the company’s stock valued at $1,045,936,000 after acquiring an additional 1,319,143 shares in the last quarter. Finally, Theleme Partners LLP raised its position in shares of Moderna by 26.9% in the fourth quarter. Theleme Partners LLP now owns 5,022,174 shares of the company’s stock valued at $1,275,532,000 after purchasing an additional 1,065,100 shares during the period. 60.11% of the stock is currently owned by hedge funds and other institutional investors.
About Moderna (NASDAQ:MRNA)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.